China: SPAC merger values YS Bio at US$834m – LaingBuisson News
YS Biopharma, previously YishengBio, a leading human use rabies vaccine manufacturing company in China’s rabies vaccine market, is merging with blank cheque company Summit Healthcare Acquisition Corp. Upon closing, the combined company will become a publicly traded company on the Nasdaq. The transaction values YS Biopharma at pre-money equity value of US$834m. Certain investors are also expected to…
You must be a HMI Subscriber to view this content.
Login » Subscribe Now »
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.